C4A and rheumatoid arthritis: Although there are no differences in C3 and C4 levels in ACPA-positive and ACPA-negative RA patients, given that complement is activated by ACPA and studies suggest a pro-inflammatory role of C3 in the example of anti-TNF therapy, targeting ACPA may provide potential therapeutic benefit for RA patients [125].